GO with less dyskinesia

Treat dyskinesia and OFF time without compromising on either. GOCOVRI^® is the only medication proven to reduce both in patients with Parkinson's disease for more GOOD ON time. Just 1 nightly dose can mean all-day coverage.^1,2

Request A Rep Peer Perspectives

Kendall, GOCOVRI patient.

Hear from real clinicians prescribing GOCOVRI

Video cover, click to watch interview with Stuart Isaacson, MD, FAAN.

The daily impact of dyskinesia and OFF time 
See the challenges real people with Parkinson’s disease face, as well as some strategies for identifying and managing dyskinesia and OFF time.

"It's my belief that we need to shift the paradigm, to focus on giving patients GOOD ON time as consistently as possible throughout the day without disruptions." –Dr. Isaacson

Video cover, click to watch interview with Robert A. Hauser, MD, MBA, FAAN and …

Video cover, click to watch interview with Dr. Robert A. Hauser and Dr. Stuart Isaacson.

Who is GOCOVRI right for?
Explore 2 case vignettes that represent patients commonly seen in clinical practice and discover what more GOOD ON time means to them.

"With a better understanding of how dyskinesia and OFF affect patients, we may be able to make more informed treatment decisions." –Dr. Hauser

Watch More Peer Perspectives

Proven results in short-term studies and evaluated in a long-term OLE study

GOCOVRI was studied in a 12-week Phase 3 trial, a 24-week Phase 3 trial, and a long-term OLE study.^1,3

View Study Results

1 nightly dose for all-day medication coverage

GOCOVRI is formulated to release slowly while your patients sleep and gradually increases plasma concentrations until the morning.²

See PK Data

Get going with GOCOVRI

With a high claims approval rate, it's easy to get your patients started with GOCOVRI Onboard^®.

Learn More

Why consider GOCOVRI?

With GOCOVRI, you don’t have to accept a trade-off between dyskinesia and OFF time. Take a closer look at how GOCOVRI works to treat both dyskinesia and OFF time in patients like yours.

Treatment Paradigm

Get clinical information on GOCOVRI

Get the latest news and updates about GOCOVRI^®, learn about upcoming events, and more.

Connect

Important Safety Information

IMPORTANT SAFETY INFORMATION AND INDICATION

CONTRAINDICATIONS

GOCOVRI is contraindicated in patients with creatinine clearance below 15 mL/min/1.73 m².

WARNINGS AND PRECAUTIONS

Falling Asleep During Activities of Daily Living and Somnolence: Patients treated with Parkinson’s disease medications have reported falling asleep during activities of daily living. If a patient develops daytime sleepiness during activities that require full attention (e.g., driving a motor vehicle, conversations, eating), GOCOVRI should ordinarily be discontinued or the patient should be advised to avoid potentially dangerous activities.

Suicidality and Depression: Monitor patients for depression, including suicidal ideation or behavior. Prescribers should consider whether the benefits outweigh the risks of treatment with GOCOVRI in patients with a history of suicidality or depression.

Hallucinations/Psychotic Behavior: Patients with a major psychotic disorder should ordinarily not be treated with GOCOVRI because of the risk of exacerbating psychosis. Observe patients for the occurrence of hallucinations throughout treatment, especially at initiation and after dose increases.

Dizziness and Orthostatic Hypotension: Monitor patients for dizziness and orthostatic hypotension, especially after starting GOCOVRI or increasing the dose.

Withdrawal-Emergent Hyperpyrexia and Confusion: Rapid dose reduction or abrupt discontinuation of GOCOVRI, may cause an increase in the symptoms of Parkinson’s disease or cause delirium, agitation, delusions, hallucinations, paranoid reaction, stupor, anxiety, depression, or slurred speech. Avoid sudden discontinuation of GOCOVRI.

Impulse Control/Compulsive Behaviors: Patients may experience urges (e.g. gambling, sexual, money spending, binge eating) and the inability to control them. It is important for prescribers to ask patients or their caregivers about the development of new or increased urges. Consider dose reduction or stopping medications.

ADVERSE REACTIONS

The most common adverse reactions (>10%) were hallucination, dizziness, dry mouth, peripheral edema, constipation, fall, and orthostatic hypotension.

INDICATION

GOCOVRI^® (amantadine) extended release capsules is indicated:

For the treatment of dyskinesia in patients with Parkinson’s disease receiving levodopa-based therapy, with or without concomitant dopaminergic medications
As adjunctive treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes

It is not known if GOCOVRI is safe and effective in children.

Please see full Prescribing Information and Patient Information.

Abbreviations: OLE, open-label extension; PK, pharmacokinetic.

References: 1. GOCOVRI^® (amantadine). Prescribing Information. Adamas Pharma LLC. 2. Hauser RA, Pahwa R, Wargin WA, et al. Pharmacokinetics of ADS-5102 (amantadine) extended release capsules administered once daily at bedtime for the treatment of dyskinesia. Clin Pharmacokinet. 2019;58(1):77-88. doi:10.1007/s40262-018-0663-4 3. Tanner CM, Pahwa R, Hauser RA, et al. EASE LID 2: a 2-year open-label trial of Gocovri (amantadine) extended release for dyskinesia in Parkinson’s disease. J Parkinsons Dis. 2020;10(2):543-558. doi:10.3233/JPD-191841